Two new anti-viral pills have been shown to be safe and effective against COVID in clinical trials, according to recent press releases. The drugs, molnupiravir, developed by Merck and Ridgeback Biotherapeutics, and Paxlovid, developed by Pfizer both appear to significantly reduce hospitalisation in people with early COVID. Some researchers are quietly hopeful that these new weapons in the anti-COVID arsenal could have a big impact, in particular in parts of the world where vaccines are still not widely available, but there are a number of caveats. In this episode of Coronapod, we open the pill boxes and pick through the contents - asking how the drugs work, what side effects we might see and how, if at all, they might change the course of the pandemic.News: COVID antiviral pills: what scientists still want to knowSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.